GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Piotroski F-Score
中文

Orgenesis (Orgenesis) Piotroski F-Score : 2 (As of Apr. 24, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Orgenesis has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Orgenesis's Piotroski F-Score or its related term are showing as below:

ORGS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 2

During the past 13 years, the highest Piotroski F-Score of Orgenesis was 6. The lowest was 2. And the median was 4.


Orgenesis Piotroski F-Score Historical Data

The historical data trend for Orgenesis's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Piotroski F-Score Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 3.00 3.00 2.00

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 3.00 1.00 2.00

Competitive Comparison of Orgenesis's Piotroski F-Score

For the Biotechnology subindustry, Orgenesis's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Orgenesis's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -19.47 + -4.127 + -12.653 + -34.392 = $-70.64 Mil.
Cash Flow from Operations was -7.24 + -5.914 + -1.181 + -0.502 = $-14.84 Mil.
Revenue was 0.142 + 6.975 + 0.11 + -13.599 = $-6.37 Mil.
Gross Profit was -2.58 + 3.743 + -0.029 + -13.761 = $-12.63 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(90.928 + 93.267 + 54.767 + 45.299 + 14.552) / 5 = $59.7626 Mil.
Total Assets at the begining of this year (Dec22) was $90.93 Mil.
Long-Term Debt & Capital Lease Obligation was $19.07 Mil.
Total Current Assets was $4.08 Mil.
Total Current Liabilities was $16.41 Mil.
Net Income was -4.009 + -5.427 + -1.356 + -4.097 = $-14.89 Mil.

Revenue was 7.212 + 7.201 + 7.988 + 13.624 = $36.03 Mil.
Gross Profit was 6.498 + 6.138 + 7.005 + 11.251 = $30.89 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(59.841 + 58.538 + 62.799 + 70.69 + 90.928) / 5 = $68.5592 Mil.
Total Assets at the begining of last year (Dec21) was $59.84 Mil.
Long-Term Debt & Capital Lease Obligation was $15.17 Mil.
Total Current Assets was $46.32 Mil.
Total Current Liabilities was $15.91 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Orgenesis's current Net Income (TTM) was -70.64. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Orgenesis's current Cash Flow from Operations (TTM) was -14.84. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-70.642/90.928
=-0.7769004

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-14.889/59.841
=-0.24880934

Orgenesis's return on assets of this year was -0.7769004. Orgenesis's return on assets of last year was -0.24880934. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Orgenesis's current Net Income (TTM) was -70.64. Orgenesis's current Cash Flow from Operations (TTM) was -14.84. ==> -14.84 > -70.64 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=19.067/59.7626
=0.31904569

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=15.166/68.5592
=0.22121028

Orgenesis's gearing of this year was 0.31904569. Orgenesis's gearing of last year was 0.22121028. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=4.076/16.407
=0.24843055

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=46.318/15.91
=2.91125079

Orgenesis's current ratio of this year was 0.24843055. Orgenesis's current ratio of last year was 2.91125079. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Orgenesis's number of shares in issue this year was 32.232. Orgenesis's number of shares in issue last year was 25.551. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-12.627/-6.372
=1.98163842

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=30.892/36.025
=0.85751561

Orgenesis's gross margin of this year was 1.98163842. Orgenesis's gross margin of last year was 0.85751561. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=-6.372/90.928
=-0.07007742

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=36.025/59.841
=0.602012

Orgenesis's asset turnover of this year was -0.07007742. Orgenesis's asset turnover of last year was 0.602012. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Orgenesis has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Orgenesis  (NAS:ORGS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Orgenesis Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Orgenesis's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (Orgenesis) Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452

Orgenesis (Orgenesis) Headlines